Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
Tue, 26th Jan 2021 20:34
Jan 26 (Reuters) - AstraZeneca Chief Executive
Pascal Soriot said on Tuesday that the British drugmaker is
working with Oxford University on a vaccine that will target the
South African variant of COVID-19.
"Having said that, we're also working on a vaccine with
Oxford University that will target the variant," Soriot told
Italian daily La Repubblica in an interview https://bit.ly/2KWidAc
published late on Tuesday.
(Reporting by Kanishka Singh in Bengaluru; Editing by Leslie
Adler)
(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).
Read more
(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.
Read more(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.
Read more(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.
Read more(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.
Read more(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.
Read moreBEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.
Read more(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.
Read more(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.
Read more(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.
Read more(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.
Read more(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.
Read more(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.
Read more(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
Read more
Last checked at